Posts Archive

NCT05308654: Phase 1: A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants with Relapsed or...

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma This is a Phase 1, open-label study to ...

PERK Inhibitor NCT05027594: Phase 1: Ph I Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Multiple Myeloma Ph I Study of...

NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD) Isa-RVD Study in Patients With Newly...

The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of...

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...

CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...

PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...

NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients This is...

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of...

NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or...

NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma...

IMPACT STUDY The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study The Immune Profiling with Antibody-based COVID-19...

DREAMM 8 Relapsed & Refractory Myeloma Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in...